second to hypertensive heart disease (HLVH) using 2D speckle tracking imaging.
Background: Breast cancer is the most frequent female cancer. Treatment of HER2+ tumours evolved with immunotherapy, leading to improved survival. Cardiac toxicity associated to trastuzumab is frequent but reversible in 75% of cases. However, only little is know about the cardiotoxicity of new anti-VEGF antibodies associated to trastuzumab. In this study, we aimed to assess the cardiac tolerance of bevacizumab associated with trastuzumab and chemotherapy in HER2+ breast cancer patients.
Methods and results:
This is a post-hoc analysis of the BEVERLY-2 study, aiming to assess the efficacy of neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2+ breast cancer. A cohort of 52 patients was prospectively included. Left ventricular ejection fraction (LVEF) was assessed by echocardiography and/or isotopic ventriculography every three months during the mean follow-up of 33±3,42 months. Mean age prior to chemotherapy was 49,75 years ±11,60. On inclusion, mean LVEF was 66,56±6,13.There was no significant difference between LVEF on inclusion and before the 5th cycle of chemotherapy fifth cycle (C5)(66,56%±6,13 vs 65,11%±7,68 ; p=0,24) ,whereas LVEF was significantly reduced at the end of the neoadjuvant therapy (62,07%±7,84 vs 66,56±6,13; p=0,0001). The nadir of LVEF was 57,87%±8,79 and occured generally during the adjuvant period. In 16 patients, LVEF decreased below 50% after neoadjuvant therapy but complete recovery of LVEF was observed in all at the end of the follow-up, 3 months after the end of the treatment (Figure 1 , next page).
Conclusion:
In this study, with an effective treatment protocol for inflammatory breast cancer, reduction in LVEF was observed in 30% of patients, however, it was reversible in all. Nadir of LVEF was observed after the final adjuvant therapy (31%). This timing and the possibility of recovery should be considered when discussing the interruption of chemotherapy because of reduced LVEF during the follow up.
Predictive genetic testing in hereditary heart diseases: a single-center series of 304 subjects
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Hereditary heart diseases are typically characterized by autosomal dominant inheritance and delayed cardiac expression. Predictive genetic testing is offered to asymptomatic relatives to allow targeted medical care with early therapeutics in order to reduce the risk of complications (sudden death, heart failure). Psychological and sociological issues related to predictive testing are however complex and have been poorly studied. Predictive genetic testing is performed in our multidisciplinary out-patient clinic dedicated to cardiogenetics since 1999.
To evaluate our practices regarding predictive genetic testing for hereditary heart diseases and study the behavior of relatives after pre-test consultation (information phase), especially regarding a waiting period that was offered before blood sampling.
We retrospectively studied records from 304 consecutive relatives seen in our department and have requested predictive genetic testing. Underlying diseases in the families were HCM (60%), DCM (17%), ARVC (15%), LQT (5%), Brugada syndrome (2%) and other (1%). A total of 21 different genes were analyzed and most frequent ones were MYBPC3 (97), MYH7 (77), LMNA (37), PKP2 (29) and TNNT2 (16). There were 260 adults and 44 minors. At the time of the first consultation, the average age was 37 years, and 83% of the relatives previously had a cardiac checkup (echocardiography for 71%).
After first multidisciplinary consultation, 22 relatives (8%) dropped out of procedure (did not performed blood sampling) and 11 relatives (3%) performed blood sampling but did not come back to know their results. Blood sample was delayed for 70% of relatives and immediate for 30%. A mutation was present in 36% of relatives (leading to careful follow-up and cascade screening in offspring) and absent in 64% (they were reassured and discharged from clinic).
We observed a high level of genetic uptake after initial consultation but a minority of relatives decided to stop or delay the procedure. These results suggest the benefit of a waiting period before blood sampling and illustrate the importance of a multidisciplinary team in this setting. Results: From 1984 to 2013, 111 first-HTx, 5 HLTx and 6 re-HTx were performed (62males), in patients aged 11.7±8.2y: 96(79%) aged <18y. Cardiopathy included 61 cardiomyopathies (50.8%), 50 CHD (41.7%), 6 retransplants (5%). HLTx included 1 Eisenmenger, 1 PPHT, and 2 pulmonary diseases. Patients with cardiomyopathy were younger than CHD (8.7y vs 14.9y).Seventeen (14%) patients had circulatory mechanical support as bridge to transplant. Acute rejection occurred more frequently within the first year post-transplant or > 5thyear in non-compliant teenagers. Overall 33 patients died (27%), 3.5±4.6y postTx (1 day
